Deciphera Pharmaceuticals (DCPH) IPO Opens Up 18%

Today's IPO for Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) opened for trading at $20.05 after pricing 7,500,000 shares of common stock at a public offering price of $17.00 per share.

In addition, Deciphera granted the underwriters a 30-day option to purchase up to 1,125,000 additional shares of its common stock at the initial public offering price.

J.P. Morgan and Piper Jaffray & Co. are acting as joint book-running managers for the offering. JMP Securities LLC is acting as lead manager and Nomura Securities International, Inc. is acting as a co-manager for the offering.

Deciphera is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off” or inactivated conformation. These investigational therapies comprise tumor-targeted agents designed to address therapeutic resistance causing mutations and immuno-targeted agents designed to control the activation of immunokinases that suppress critical immune system regulators, such as macrophages. We have used our platform to develop a diverse pipeline of tumor-targeted and immuno-targeted drug candidates designed to improve outcomes for patients with cancer by improving the quality, rate and/or durability of their responses to treatment.

You May Also Be Interested In